Maintenance Therapy Study for Recurrent Ovarian Cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent ovarian, fallopian tube, or primary peritoneal cancer that is platinum-sensitive (responded to platinum-based chemo before).
- You have received 4 or more cycles of platinum-based chemo as first treatment, and 6 to 8 cycles of carboplatin-based chemo for the second round.
- You have not had more than 2 prior lines of treatment for your ovarian cancer.
- You are in generally good health (able to do daily activities) with a performance status of 0 or 1.
- You have a tumor sample available that was not previously treated with radiation.
- You do not have severe eye problems, active inflammatory bowel disease, uncontrolled heart or blood vessel disease, or certain other lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This study tests a new drug, Raludotatug Deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as ongoing treatment after initial chemotherapy for recurrent ovarian cancer. It aims to see if this maintenance treatment helps keep the cancer from coming back longer.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.